6 stories mentioning SHA:688617Updated just now
Every FINWIRES story that references SHA:688617, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
APT Medical (SHA:688617) vice chairman and major shareholder Cheng Zhenghui will offload up to 2.1 million shares, according to a Monday filing with the Shanghai bourse.The shares to be offloaded represent up to 1.5% of the total shares of the cardiovascular interventional medical device maker.APT's shares rose 1% during recent trade on Monday.
APT Medical's (SHA:688617) attributable profit rose 26% to 537.3 million yuan in the first half from 425.2 million yuan in the year-ago period, according to a Thursday filing with the Shanghai Stock Exchange.Earnings per share at the Chinese cardiovascular interventional medical device maker increased to 3.82 yuan from 3.01 yuan in the prior-year period.Operating revenue grew 26% year over year to 1.53 billion yuan from 1.21 billion yuan.
APT Medical (SHA:688617) plans to waive its preemptive rights in the transaction where Vice Chair Cheng Zhenghui will acquire 25% of controlling subsidiary Haoying Medical for 112.5 million yuan.Post-transaction, the medical device maker will retain 63.48% ownership and control of Haoying Medical, according to a Thursday filing with the Shanghai bourse.Cheng holds a 16.68% stake in APT Medical.Shares of the company rose 4% in recent trade.
APT Medical (SHA:688617) has an average rating of buy and mean price target of 335.39 yuan, according to analysts polled by FactSet.
APT Medical (SHA:688617) said Chair Zhao Yuxiang plans to purchase between 2 million yuan and 3 million yuan worth of company shares between May 11 and May 31.Zhao currently holds no shares, according to a Tuesday filing with the Shanghai bourse.Shares of the medical device maker rose 3% in recent trade.
APT Medical (SHA:688617) appointed Zhao Yuxiang chairman, according to a Shanghai bourse filing on Friday.Zhao will take over from Ge Hao, who resigned due to changes in work arrangements but will continue to serve as a director of the Chinese medical device maker.
